Project|21's first patron, German internet entrepeneur Michael Greve, has formally announced a list of the research efforts that will be supported over the next year by the initial $1m tranche of his donation - as well as the startup companies receiving seed funds.

Our newest paper has just been published in Nucleic Acids Research, demonstrating the simultaneous rescue of two mitochondrial mutations by new nuclear genes. We're grateful to everyone who donated to our 2015 crowdfunding campaign, which paid for this study!

SENS Research Foundation has commissioned a series of 8 animations, narrated by actor Edward James Olmos, to explain the concept of SENS and some of the therapies that we're developing to end age-related disease for good.

The extraordinary costs of drug development could be mitigated by adopting a less secretive approach in the early stages of research, according to a new article in Nature - citing work published early this year by SRF Summer Scholar Zeeshan Arshad and co-authors.

Michael Greve, the first donor to our Project|21 campaign, gave a presentation at RB2016 discussing how his life led to a passionate interest in the long-term maintenance of human health - and ultimately his decision to commit $10 million to our work.

The 2016 Rejuvenation Biotechnology Conference was our first major event to be live streamed, with viewers tuning in from 62 countries. For those who weren't able to join the stream, a full recording is now available to watch in our video library!

Project|21 is a new initiative created by SENS Research Foundation to advance rejuvenation biotechnology to human clinical trials by 2021, through three complementary programs: the Bridge Fund, the Center of Excellence, and the Alliance Program.

Join Aubrey de Grey, Chief Science Officer of the SENS Research Foundation, on a tour of our Research Center in Mountain View, CA, and learn more about our Control ALT, Delete Cancer campaign. Filmed in 360-degree virtual reality!

Planning ahead for the holiday season? When you use our Amazon Smile link to purchase your gifts, Amazon automatically donates part of your payment to SRF - and it won't cost you an extra cent!

Check out all the latest news from SENS Research Foundation in our second September newsletter. You might also like to check out the archive of past messages, or subscribe to our mailing list to make sure you don't miss out on future updates!

Internet entrepreneur Michael Greve is the first donor to our new Project|21 campaign, with a gift of $5 million towards SENS research programs. Michael has also pledged a further $5 million in seed funding for startups in the field of rejuvenation biotechnology.

Veteran longevity science blogger Reason highlights the significance of SRF's new Control ALT, Delete Cancer campaign within the broader context of cancer research, and interviews lead researcher Dr. Haroldo Silva.

Entrepreneur and biohacker Dave Asprey recently interviewed our Chief Science Officer, Dr. Aubrey de Grey, for the health podcast Bulletproof Radio. Their in-depth conversation covers a broad range of topics related to our current work and future plans.

Our general introduction to SENS research, Ending Aging, is now available in audiobook format. All profits will go to SENS Research Foundation. If Ending Aging is your first purchase as a new Audible member, we also get a $50 "bounty" - so please consider signing up!

A new article in Genetic Engineering & Biotechnology News explores how applying regenerative medicine to the accumulated damage of aging is becoming an increasingly mainstream idea, crediting SRF CSO Aubrey de Grey as a pioneer in the field.

Our CSO Dr. Aubrey de Grey, and Buck Institute for Research on Aging CEO Brian Kennedy, successfully opposed the motion that "Lifespans Are Long Enough" in debate at the Kaufman Center on February 3rd. A full video of the debate is now available.

An SRF-funded study by Yale University Professor David Spiegel has been published in world-leading journal Science. The discoveries announced will accelerate future research in the fields of diabetes and age-related tissue cross-linking.